Alnylam Pharmaceuticals Inc

ALNY: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
rKQLOCK|Jr#wLOCK|>>&@!S$

Alnylam Earnings: Shares Tank Amid Reduced Outlook for Key ATTR Franchise

Alnylam posted second-quarter net product revenue of nearly $1.2 billion, up 74% compared with the prior-year period, driven by total ATTR franchise sales exceeding $1 billion. Management cut its 2026 ATTR sales guidance by $200 million at the midpoint and shares fell 28% on July 30.

Sponsor Center